Treats hypertension. ANDA 90492, held by Sun Pharm. Diltiazem Hydrochloride.
As of Nov 16, 2026, ANDA 90492 (Diltiazem Hydrochloride), held by Sun Pharm, was first approved by FDA on Oct 28, 2011, with 2 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Diltiazem hydrochloride extended-release capsules (Once-a-day dosage) are indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive medications. Diltiazem hydrochloride extended-release capsules (Once-a-day dosage) are indicated for the management of chronic stable angina and angina due to coronary artery spasm.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 28, 2011 | Original application | Approved | None posted |
| Diltiazem Hydrochloride120MG · capsule, extended release;oral | Diltiazem Hydrochloride | Discontinued |
| Diltiazem Hydrochloride180MG · capsule, extended release;oral | Diltiazem Hydrochloride | Discontinued |
| Diltiazem Hydrochloride240MG · capsule, extended release;oral | Diltiazem Hydrochloride | Discontinued |
| Diltiazem Hydrochloride300MG · capsule, extended release;oral | Diltiazem Hydrochloride | Discontinued |
| Diltiazem Hydrochloride360MG · capsule, extended release;oral | Diltiazem Hydrochloride | Discontinued |
| Nov 21, 2024 | Supplement 8Labeling · Standard review | Approved | None posted |
| Nov 21, 2024 | Supplement 19Labeling · Standard review | Approved | None posted |
| Oct 28, 2011 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters